The pharmaceutical industry is one of the most dynamic and innovative sectors in the world. It is constantly developing new drugs and treatments to address various health challenges and improve the quality of life of millions of people. However, not every pharma company is successful in producing positive clinical trial results. If you just took a quick glance at the performance charts of a couple of biotech focused exchange traded funds (ETFs), such as ARK Genomic Revolution ETF (NYSEARCA:ARKG)

PALO ALTO, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on September 06, 2023, the compensation committee of BridgeBio’s board of directors granted twenty-four new employees restricted stock units for an aggregate of 154,186 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted

PALO ALTO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Tuesday, September 12 at 10:50 am ET. To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page wi

- BridgeBio completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and a scientific advice engagement with the European Union (EU) European Medicines Agency (EMA) - FDA and EMA alignment was reached on the adequacy of a one-year, 2:1 randomized, placebo-controlled Phase 3 pivotal trial for infigratinib to support a marketing application for the treatment of children with achondroplasia - The primary endpoint will be change from baseline in annualized height velocit

Shares of BBIO stock slumped Monday as analysts parsed through BridgeBio Pharma's effort to take on Pfizer in treating a heart condition.

- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consistently favored acoramidis treatment across key subgroups, including across both variant and wild-type ATTR patients as well as across New York Heart Association (NYHA) Class I, II, and III patients. In particular, in contrast to results observed in prior studies of TTR stabilizers, consistency against cardiovascular-related hospitalizations (CVH) was ob

PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3 results from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, or ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2023, taking place in Amsterdam, Netherlands on August 25 - 28, 2023. ATTRibut

In this article, we discuss 15 best performing stocks in the last 6 months. If you want to skip our detailed discussion on the stock market, head directly to 5 Best Performing Stocks in the Last 6 Months. As per BlackRock’s findings, equity performance has surpassed predictions in the first half of 2023. In spite […]

Andreas Halvorsen (Trades, Portfolio), a renowned investment guru, recently filed his 13F report for the second quarter of 2023, which ended on June 30, 2023.

Wall Street can sometimes wax enthusiastic over young biotechs -- perhaps too much so. Let's dive in and analyze its plans for the next year to see if Wall Street has it right. It has a pair of commercialized programs, and three others in phase 3 clinical trials.